Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis
出版年份 2017 全文链接
标题
Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-11-13
DOI
10.1038/s41598-017-16101-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials
- (2017) Ahmed N. Mahmoud et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis
- (2017) Gyeongsil Lee et al. PLoS One
- Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials
- (2016) Edoardo Mannucci et al. ADVANCES IN THERAPY
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
- (2016) Jamie Wroge et al. ANNALS OF PHARMACOTHERAPY
- Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
- (2016) Ling Li et al. BMC Cardiovascular Disorders
- Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
- (2016) Keith C. Ferdinand et al. Cardiovascular Diabetology
- Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
- (2016) Marina V. Basalay et al. CARDIOVASCULAR RESEARCH
- Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials
- (2016) Tiansheng Wang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials
- (2016) M. E. Shomali et al. DIABETIC MEDICINE
- Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis
- (2016) Je-Yon Kim et al. PLoS One
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix
- (2015) Emma Robinson et al. BASIC RESEARCH IN CARDIOLOGY
- Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
- (2015) Rafael Simó et al. Cardiovascular Diabetology
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
- (2015) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
- (2015) R. S. Weinstock et al. DIABETES OBESITY & METABOLISM
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis
- (2015) Gert van Valkenhoef et al. Research Synthesis Methods
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
- (2014) J. Reusch et al. DIABETES OBESITY & METABOLISM
- Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study
- (2014) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
- (2014) Peter N. Weissman et al. DIABETOLOGIA
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
- (2013) Francesco Giorgino et al. Annals of the New York Academy of Sciences
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
- (2013) Anthony H. Barnett et al. CLINICAL DRUG INVESTIGATION
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES CARE
- Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study
- (2013) H. Yki-Jarvinen et al. DIABETES CARE
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes
- (2013) J. Rosenstock et al. DIABETIC MEDICINE
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial
- (2013) Burkhard Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials
- (2013) S. Wu et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension
- (2012) A. H. Barnett et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis
- (2012) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*
- (2012) Adrian S. DOBS et al. Journal of Diabetes
- Heart in Diabetes: A Microvascular Disease
- (2011) M. Laakso DIABETES CARE
- Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
- (2011) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
- (2011) M. Nagashima et al. DIABETOLOGIA
- Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
- (2011) Tina Ken Schramm et al. EUROPEAN HEART JOURNAL
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
- (2010) Y. Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started